



QUIZZARIA

Inter-college Pre and Para Clinical Quiz

Sunday, 31st May, 2026

ESIC Medical College & Hospital, Faridabad, Haryana

A memorable day at ESIC Medical College & Hospital, Faridabad!

The collaborative initiative of Indian Society of Haematology & Blood Transfusion (ISHBT) and IMA MSN, Haryana, culminated in a spectacular 3-hour All India Undergraduate Medical College Quiz, celebrating academic excellence and the spirit of healthy competition. The journey began with the online preliminary round held on 31st May, which witnessed an overwhelming response from more than 50

medical colleges and over 350 undergraduate medical students from across the country. The top 30 finalists earned the opportunity to compete in the Grand Finale held today at ESIC MCH, Faridabad. Congratulations to the overall champion from Maulana Azad Medical College (MAMC), New Delhi, for securing the top position. Heartiest congratulations also to all the finalists and winners for their outstanding performance. Every participant was awarded a certificate in recognition of their achievement. The top five winners, along with the Organising Committee, are featured in the photograph with the ISHBT logo proudly displayed in the background. This landmark initiative reflects ISHBT's commitment to promoting academic excellence, encouraging undergraduate participation in haematology, and inspiring the next generation of medical professionals. Congratulations to all the participants, faculty members, organisers, and volunteers who made this event a grand success!

COAGULATION Way Forward

Saturday, 6th June, 2026

Sheraton Grand Hotel, Pune

The COAGULATION Way Forward conference is a premier academic forum dedicated to the latest advances in coagulation disorders, haemostasis, thrombosis, laboratory diagnostics, and evolving therapeutic strategies. The meeting will bring together leading national experts, clinicians, laboratory physicians, researchers, and trainees to exchange knowledge, discuss challenging clinical scenarios, and explore recent developments in coagulation science and patient care. The scientific programme will feature expert lectures, interactive panel discussions, case-based learning sessions, and opportunities for professional networking, making it an enriching educational experience for healthcare professionals involved in the diagnosis and management of bleeding and thrombotic disorders. We cordially invite haematologists, pathologists, transfusion medicine specialists, physicians, postgraduate students, and researchers to participate in this important academic event and contribute to advancing excellence in coagulation practice.



Integrated Approach to Hematopathology:

Morphology, Immunophenotyping and Molecular Correlation

CME and Hands-On Workshop - From Morphology to Molecular Diagnosis

Thursday, 18th June, 2026

Armed Forces Medical College, Pune

The Indian Society of Hematology & Blood Transfusion (ISHBT), in collaboration with the Department of Pathology, Armed Forces Medical College (AFMC), Pune, is organizing a Continuing Medical Education (CME) and Hands-on Workshop titled "Integrated Approach to Hematopathology: Morphology, Immunophenotyping and Molecular Correlation" on 18 June 2026 at the Department of Pathology, AFMC, Pune. Conducted by Brig (Dr.) Tathagata Chatterjee (Retd.), President of ISHBT and a distinguished

consultant in Hematology and Pathology, the workshop is designed to bridge the gap between conventional morphology and advanced molecular diagnostics. The programme will provide participants with practical training in peripheral blood smear interpretation, bone marrow morphology, flow cytometry, immunohistochemistry, FISH, and molecular testing, while highlighting common diagnostic pitfalls through interactive case discussions and slide seminars. Tailored for postgraduate students, practicing pathologists, hematologists, laboratory medicine professionals, and faculty members, this integrated educational initiative aims to enhance diagnostic accuracy, strengthen clinicopathological correlation, and promote evidence-based patient care in hematological disorders.

Attention All ISHBT Life Members

All ISHBT Life Members are requested to log in to the ISHBT Member Portal and regularly update their correspondence details to ensure uninterrupted communication from the Society.

Member Login: <https://ishbtish.com/?p=web/login>

ISHBT Website: www.ishbtish.com

Keeping your profile up to date will help you receive important communications and member benefits, including: ISHBT Guidelines and Publications, Journals, Annual Circular, Newsletters, Election Circulars, Academic updates, announcements, and other important information from ISHBT.

Your cooperation in maintaining accurate correspondence details is highly appreciated and will ensure that you continue to receive all official communications and member services without interruption.



Register Now - www.haematocon2026.in



Upcoming CMEs of ISHBT
National Coagulation Conclave 2026
Organised by:
Indian Society of Haematology & Blood Transfusion & Indian College of Haematology
In associate with
Dept. of Haematology, SGPGIMS, Lucknow
Organizing Secretary: Dr Dinesh Chandra
Date: 24th - 25th July, 2026
Venue: Lecture Theatre Complex, SGPGIMS, Lucknow, U. P.
Register Now -
https://docs.google.com/forms/d/e/1FAIpQLSeoaYZ4tAf1bV_S9hQVBGP-46gBHGFTfyNkmeCHiWallTTaA/viewform



Masterclass of ISHBT
48th Masterclass of ISHBT
Topic: Managing high risk MDS
Speaker: Dr. Meet Kumar
Date: Wednesday, 15th July, 2026,
Time: 07:00 P.M. IST
<https://forms.gle/hswZKtAz16ClIkGdA>


Indian Journal of Haematology & Blood Transfusion (IJHBT)
Publishing model - Hybrid
Volume: 42, Issue: 4, July, 26
75 articles in this issue



Click below link to read or download
<https://link.springer.com/journal/12288/volumes-and-issues/42-4>

ISHBT Annual Circular 2026
Link to Download -
<https://ishbtish.com/imgs/circular/Annual%20Circular%202026.pdf>
ISHBT Election 2026 Circular
Link to Download -
<https://ishbtish.com/imgs/pdf/Election%20Circular%202026.pdf>
ISHBT Election 2026 - Nomination Form
Link to Download -
<https://ishbtish.com/imgs/pdf/Election%20Nomination%20Form%202026.pdf>

Guideline By Indian College of Hematology (ICH)




Available On
Jaypee Brothers Medical Publishers,
Amazon & AIBH
<https://ishbtish.com/ich/guidelines.html>

What's new in Haematology in June, 2026 in Myeloma & Lymphoma

Myeloma
Study: Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. Dimopoulos M, Schjesvold F, Fu C et al. The Lancet, 2026 Jun 14: S0140-6736(26)01088-3. doi: 10.1016/S0140-6736(26)01088-3
Interpretation
Mezigdomide–carfilzomib–dexamethasone provided a significant PFS benefit compared with carfilzomib –dexamethasone alone, with higher rates of grade 3 or 4 adverse events, including infections, which were mostly manageable with standard clinical practice and supportive care. These findings support mezigdomide–carfilzomib –dexamethasone as a clinically meaningful treatment option as early as first relapse in predominantly triple-class-exposed, anti-CD38 antibody-refractory and lenalidomide-refractory patients, a growing population with substantial unmet need.
THE LANCET

Study II: Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. N Engl J Med. 2026 Jun 13. doi: 10.1056/NEJMoa2604657. Epub ahead of print. PMID: 42294841. Mina R, Beksac M, Rodríguez-Otero P, Chen W, Mateos MV et al.
Conclusions: Among patients with relapsed or refractory multiple myeloma who had previously received at least one line of therapy, both Tal-DP (talquetamab plus daratumumab and pomalidomide) and Tal-D (talquetamab plus daratumumab) led to significantly longer progression-free survival than DPd (daratumumab plus pomalidomide and dexamethasone).



Lymphoma
Study I: Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients with Mantle Cell Lymphoma Previously Treated with Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor. Toby A Eyre, Yuqin Song, Olivier Hermine Et al. J Clin Oncol 2026 Jul 1: JCO2600550. doi: 10.1200/JCO-26-00550.
Conclusion: Sonrotoclax demonstrated rapid, durable responses and manageable safety in heavily pretreated patients with R/R MCL, including high-risk subgroups, supporting its further clinical evaluation as an oral therapy for R/R MCL.
Journal of Clinical Oncology

Study II: Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis. Nicolas Gower, Pierre Feugier , Jason Westin et al. Blood 2026 Jun 18;147(25):3061-3068. doi: 10.1182/blood.2026033126.
In conclusion, the final analysis of RELEVANCE confirmed the absence of differences in efficacy outcomes between R2 and R-Chemo and the lack of new safety concerns, positioning R2 as a valid chemo-free alternative for patients with previously untreated, advanced FL. We believe these 10-year follow-up results constitute a benchmark for long-term expectations and comparisons with new promising chemo-free combinations currently tested in the front-line setting of FL.
blood